- Home
- VBNK vs AUTL Comparison
VBNK vs AUTL Comparison
Compare VBNK & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBNK
- AUTL
- Stock Information
- Founded
- VBNK 1980
- AUTL 2014
- Country
- VBNK Canada
- AUTL United Kingdom
- Employees
- VBNK N/A
- AUTL N/A
- Industry
- VBNK Commercial Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VBNK Finance
- AUTL Health Care
- Exchange
- VBNK Nasdaq
- AUTL Nasdaq
- Market Cap
- VBNK 374.8M
- AUTL 368.6M
- IPO Year
- VBNK 2021
- AUTL 2018
- Fundamental
- Price
- VBNK $11.65
- AUTL $1.24
- Analyst Decision
- VBNK Buy
- AUTL Strong Buy
- Analyst Count
- VBNK 1
- AUTL 3
- Target Price
- VBNK $13.00
- AUTL $8.33
- AVG Volume (30 Days)
- VBNK 44.2K
- AUTL 2.4M
- Earning Date
- VBNK 12-08-2025
- AUTL 11-12-2025
- Dividend Yield
- VBNK 0.61%
- AUTL N/A
- EPS Growth
- VBNK N/A
- AUTL N/A
- EPS
- VBNK 0.69
- AUTL N/A
- Revenue
- VBNK $82,297,771.00
- AUTL $51,128,000.00
- Revenue This Year
- VBNK $12.20
- AUTL $643.50
- Revenue Next Year
- VBNK $30.76
- AUTL $108.69
- P/E Ratio
- VBNK $18.17
- AUTL N/A
- Revenue Growth
- VBNK 0.07
- AUTL 406.67
- 52 Week Low
- VBNK $8.51
- AUTL $1.11
- 52 Week High
- VBNK $18.38
- AUTL $3.45
- Technical
- Relative Strength Index (RSI)
- VBNK 47.40
- AUTL 38.88
- Support Level
- VBNK $11.25
- AUTL $1.20
- Resistance Level
- VBNK $11.72
- AUTL $1.35
- Average True Range (ATR)
- VBNK 0.30
- AUTL 0.09
- MACD
- VBNK -0.00
- AUTL -0.01
- Stochastic Oscillator
- VBNK 51.28
- AUTL 12.50
About VBNK VersaBank
VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.